Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 29:28:127-138.
doi: 10.1016/j.jare.2020.08.012. eCollection 2021 Feb.

Therapeutic advances of miRNAs: A preclinical and clinical update

Chiranjib Chakraborty  1   2 , Ashish Ranjan Sharma  2 , Garima Sharma  3 , Sang-Soo Lee  2
Affiliations
Review

Therapeutic advances of miRNAs: A preclinical and clinical update

Chiranjib Chakraborty et al. J Adv Res. .

Abstract

miRNAs, a class of small endogenous RNAs, are one of the essential biopharmaceuticals which are in commercial spans as next-generation medicine in recent times. A snapshot of the current scenario regarding the miRNAs as biopharmaceuticals have been discussed. In this work, biopharmaceutical companies working with miRNAs and the current status of preclinical/clinical trials about miRNA therapeutics have been reviewed. Finally, recent updates on the absorption, distribution, metabolism, and excretion (ADME), as well as a delivery system of miRNAs, have been illustrated.

Keywords: Biopharmaceuticals; Next-generation medicine; miRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
The potential of miRNAs in the treatment of human diseases.
Fig. 2
Fig. 2
Differentpatents of miRNAs (A) Total no of patents search from US patent database, the European patent office database and Google patent database (quick search through the keyword “miRNA”) (B) Number of patents in “miRNA” in case of the different diseases (from US patent database) (C) Number of patents in “miRNA” in case of the different diseases (from European patent office database) (D) Number of patents in “miRNA” in event of the different type of cancers (quick Search from Google patent database)(search was performed on 9th June 2020).
Fig. 3
Fig. 3
The different stages of the therapeutic miRNA development procedure. A snapshot of all the stages, beginning from “miRNA discovery” to “miRNA therapeutics in the market”.
See this image and copyright information in PMC

References

    1. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854. - PubMed
    1. Pasquinelli A.E. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86. - PubMed
    1. Reinhart B.J. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901. - PubMed
    1. Bhattacharya M. The crucial role and regulations of miRNAs in zebrafish development. Protoplasma. 2017;254(1):17–31. - PubMed
    1. Chakraborty C. miRNAs in insulin resistance and diabetes-associated pancreatic cancer: the 'minute and miracle' molecule moving as a monitor in the 'genomic galaxy'. Curr Drug Targets. 2013;14(10):1110–1117. - PubMed